KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Finished Goods: 2023-2025

Historic Finished Goods for Aurinia Pharmaceuticals (AUPH) over the last 1 years, with Sep 2025 value amounting to $1.4 million.

  • Aurinia Pharmaceuticals' Finished Goods was N/A to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $903,000 for FY2024, which is 54.89% up from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Finished Goods is $1.4 million, which was down 46.05% from $2.6 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Finished Goods high stood at $3.7 million for Q1 2025, and its period low was $583,000 during Q4 2023.
  • Its 3-year average for Finished Goods is $1.8 million, with a median of $1.4 million in 2025.
  • Data for Aurinia Pharmaceuticals' Finished Goods shows a peak YoY spiked of 54.89% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Aurinia Pharmaceuticals' Finished Goods stood at $583,000 in 2023, then surged by 54.89% to $903,000 in 2024, then reached $1.4 million in 2025.
  • Its Finished Goods was $1.4 million in Q3 2025, compared to $2.6 million in Q2 2025 and $3.7 million in Q1 2025.